These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2177543)

  • 1. [Effects of exogenous surfactants on mortality and main complications of hyaline membrane disease].
    Walti H; Relier JP
    Pediatrie; 1990; 45(10):657-63. PubMed ID: 2177543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hyaline membrane disease in the premature infant: diagnostic aspects and therapeutic prospects (excluding mechanical ventilation)].
    Dehan M
    Rev Prat; 1989 Sep; 39(21):1844-8. PubMed ID: 2814266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Exogenous surfactants].
    Dehan M; Denizot B
    Arch Fr Pediatr; 1989 Feb; 46(2):85-7. PubMed ID: 2660764
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyaline membrane disease (HMD) therapy in Latin America: impact of exogenous surfactant administration on newborn survival, morbidity and use of resources.
    Rossello JD; Hayward PE; Martell M; Del Barco M; Margotto P; Grandzoto J; Bastida J; Peña J; Villanueva D
    J Perinat Med; 1997; 25(3):280-7. PubMed ID: 9288665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of severe hyaline membrane disease with a single-dose of natural exogenous surfactant of porcine origin. A randomized trial: immediate effects and outcome at 28 days of life].
    Walti H; Relier JP; Huon C; Monset-Couchard M; Scemama M; De Gamarra E; Moriette G; Curstedt T; Robertson B
    Arch Fr Pediatr; 1990 May; 47(5):329-34. PubMed ID: 2196030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital.
    Supapannachart S; Limrungsikul A; Khowsathit P
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1252-8. PubMed ID: 12549803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Problems posed by the development of exogenous surfactants for the treatment of hyaline membrane disease].
    Denizot BA; Tchoreloff PC; Bonanno LM; Proust JE; Lindenbaum A; Dehan M; Puisieux F
    Ann Pharm Fr; 1990; 48(5):242-7. PubMed ID: 2088159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Surgical treatment of the ductus arteriosus in premature infants].
    Ochoa-Ramírez E; Puente-Ledezma JF; Hinojosa-Pérez JO; Cervantes F
    Gac Med Mex; 1983 Jul; 119(7):295-9. PubMed ID: 6680105
    [No Abstract]   [Full Text] [Related]  

  • 9. Surfactant for hyaline membrane disease.
    Fujiwara T; Adams FH
    Pediatrics; 1980 Nov; 66(5):795-8. PubMed ID: 7432888
    [No Abstract]   [Full Text] [Related]  

  • 10. Early and late surfactant treatments in baboon model of hyaline membrane disease.
    Maeta H; Vidyasagar D; Raju TN; Bhat R; Matsuda H
    Pediatrics; 1988 Feb; 81(2):277-83. PubMed ID: 3340477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaline membrane disease treated with bovine surfactant.
    Smyth JA; Metcalfe IL; Duffty P; Possmayer F; Bryan MH; Enhorning G
    Pediatrics; 1983 Jun; 71(6):913-7. PubMed ID: 6687937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vitamin E and bronchopulmonary dysplasia in pulmonary hyaline membrane disease].
    Zanardo V; Romanelli M; Pesenti P; Mittiga S; Marcazzò L; Benini F
    Acta Vitaminol Enzymol; 1982; 4(3):221-6. PubMed ID: 6756098
    [No Abstract]   [Full Text] [Related]  

  • 13. [Ligation of the ductus arteriosus in premature infants. Surgical considerations].
    Ochoa E; Puente F; Cervantes F; Hinojosa O; Avila R
    Arch Inst Cardiol Mex; 1981; 51(2):173-7. PubMed ID: 7247584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison outcomes of surfactant therapy in respiratory distress syndrome in two periods.
    Chotigeat U; Promwong N; Kanjanapattanakul W; Khorana M; Sangtawesin V; Horpaopan S
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S109-14. PubMed ID: 19253505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hyaline membrane disease by human amniotic fluid surfactant.
    Jin HZ; Chen C; Jin QL; Shao XM
    Chin Med J (Engl); 1989 Dec; 102(12):944-6. PubMed ID: 2517741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bovine surfactant (surfactant TA) therapy in immature baboons with hyaline membrane disease.
    Vidyasagar D; Maeta H; Raju TN; John E; Bhat R; Go M; Dahiya U; Roberson Y; Yamin A; Narula A
    Pediatrics; 1985 Jun; 75(6):1132-42. PubMed ID: 3846883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High frequency oscillation ventilation after surfactant use in hyaline membrane disease. Outcome of ventilation parameters].
    Claris O; Lapillonne A; Madinier-Chappat N; Miguet D; Salle BL
    Cah Anesthesiol; 1994; 42(3):325-8. PubMed ID: 7812856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The therapeutic use of pulmonary surfactant in neonatal hyaline membrane disease].
    Lozano-González CH; Piña-Ceballos VM; Beyer-Obezo J; Gutiérrez-Martín A; Martínez-Hinojosa B; Flores-Támez ME
    Bol Med Hosp Infant Mex; 1993 Jul; 50(7):481-91. PubMed ID: 8363747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Provo multicenter early high-frequency oscillatory ventilation trial: improved pulmonary and clinical outcome in respiratory distress syndrome.
    Gerstmann DR; Minton SD; Stoddard RA; Meredith KS; Monaco F; Bertrand JM; Battisti O; Langhendries JP; Francois A; Clark RH
    Pediatrics; 1996 Dec; 98(6 Pt 1):1044-57. PubMed ID: 8951252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Premature infants weighing less than 1000 grams: mortality, morbidity and short-term neurologic outcome].
    Claris O; Claris-Meunier G; Gay C; Putet G; Salle B
    Pediatrie; 1990; 45(10):709-14. PubMed ID: 2177548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.